Clinical Trial Update: Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating Envafolimab in combination with Endostar as first-line treatment for advanced lung neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Neoplasms

Drugs mentioned

• Endostar (recombinant human endostatin)
• Envafolimab (envafolimab)

Snippet

Sponsor: The First People's Hospital of Lianyungang | Conditions: Lung Neoplasms | Phase 2 | Status: UNKNOWN